BMRN Adcom from nov 24...things that make you go hmmmm
...so as i posted earlier as a comparable to TST Adcom folks should compare it to BMRN Adcom from yesterday, i will not focus on the various differences and focus on what is just useful (i was unable to listen to the event but get my viewpoints from a) my read of the FDA briefing documents and b) various opinions on yesterday events)..
..but 1st off and criticially important to ponder is this BMRN was in a trading halt all day yesterday...that is right BMRN a $15B market cap company whose DMD drug candidate is a small portion of their overall portfolio was in a trading halt..so the extremely important hard question to demand an answer of from TST leadership why wasn't TST a single drug whose entire market cap is wrapped up in MCNA under a trading halt during the entire day of its AdCom...i will very likely be making a formal complaint to IIROC in this matter as i believe any company statement in this regard is not believable (ie the entire proper and honest truth)...was TST allowed to trade to transfer wealth???? gotta wonder as IME SOP for most non-hugo biotechs/pharmas is to halt trading during AdCom as the flow of information is 100% assymetric to those who listen or are there
..2 FDA briefing documents and the market reaction to them are typically a "tell" as to AdCom results...BMRN traded down before AdCom after FDA briefing documents and a bigger tell is that SRPT (a competitor to BMRN) rocketed up 30%, TST had no comparable sell off (which in TST's case would've likely been -$0.50)
..i suggest you read "the Street" commentary on BMRN...i believe FDA officials are quoted as stating their belief the BMRN DMD candidate would kill DMD patients....as i stated before bad safety = non=approvable....
..so BMRN as one of many benchmarks, and to that whiner that attacked me on another company long ago that i won't name as it is irrelevant vs BMRN which is very current and very relevant, leads me again to conclude that MCNA is approvable and i believe will be approved.
PS..interest tidbit from the street, the commentator suggested the FDA will select members to an AdCom to support their view (hmmmm)
regards